Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial.
Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, Williams HC; U.K. Dermatology Clinical Trials Network's STOP GAP team. Mason JM, et al. Among authors: ormerod ad. Br J Dermatol. 2017 Dec;177(6):1527-1536. doi: 10.1111/bjd.15561. Epub 2017 May 31. Br J Dermatol. 2017. PMID: 28391619 Free PMC article. Clinical Trial.
Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.
Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC; UK Dermatology Clinical Trials Network's STOP GAP Team. Thomas KS, et al. Among authors: ormerod ad. J Am Acad Dermatol. 2016 Nov;75(5):940-949. doi: 10.1016/j.jaad.2016.06.016. Epub 2016 Aug 5. J Am Acad Dermatol. 2016. PMID: 27502313
A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.
Chalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, Foster KA, Whitham D, Williams HC; BLISTER study group. Chalmers JR, et al. Br J Dermatol. 2015 Jul;173(1):227-34. doi: 10.1111/bjd.13729. Epub 2015 May 26. Br J Dermatol. 2015. PMID: 25683592 Clinical Trial.
Generating new evidence, improving clinical practice and developing research capacity: the benefits of recruiting to the U.K. Dermatology Clinical Trials Network's STOP GAP and BLISTER trials.
Batchelor JM, Chapman A, Craig FE, Harman KE, Kirtschig G, Martin-Clavijo A, Ormerod AD, Walton S, Williams HC. Batchelor JM, et al. Among authors: ormerod ad. Br J Dermatol. 2017 Nov;177(5):e228-e234. doi: 10.1111/bjd.15959. Epub 2017 Nov 10. Br J Dermatol. 2017. PMID: 29124728
Compulsory registration of clinical trials.
Ormerod AD, Williams HC. Ormerod AD, et al. Br J Dermatol. 2005 May;152(5):859-60. doi: 10.1111/j.1365-2133.2005.06727.x. Br J Dermatol. 2005. PMID: 15888137 No abstract available.
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. Among authors: ormerod ad. Br J Dermatol. 2019 Feb;180(2):329-337. doi: 10.1111/bjd.17036. Epub 2018 Oct 21. Br J Dermatol. 2019. PMID: 30070708 Free PMC article.
165 results